Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Correvio Pharma Corp. CORV

Correvio Pharma Corp is specialty pharmaceutical company. It offers patients and healthcare providers therapeutic solutions for acute medical conditions to improve health and quality of life. Its products are Aggrastat, Esmocard, Brinavess, Xydalba, Zevtera/Mabelio, and others. It offers solutions on Acute Bacterial Skin and Skin Structure Infections, Acute Coronary Syndromes, Atrial Fibrillation, Hospital Acquired Pneumonia & Community Acquired Pneumonia, Pulmonary Arterial Hypertension, and Su


NDAQ:CORV - Post by User

Comment by bigkaganon Dec 06, 2019 7:50pm
148 Views
Post# 30431047

RE:Will test $1.65 Canadian

RE:Will test $1.65 Canadianthe reason for the sell-off was that some anonymous staffers at FDA badmouthed Brinavess as "too dangerous" but it still could be approved with some limitations when the experts meet on Dec.10 IMHO
<< Previous
Bullboard Posts
Next >>